UNLABELLED: Methotrexate is used to manage moderate to severe psoriasis and psoriatic arthritis. Methotrexate acts by inhibiting the enzymes involved in nucleotide synthesis. Methotrexate polyglutamates (MTXPGs) have a higher potency to inhibit Dihydrofolate reductase (DHFR), 5-aminoimidazole-4-carboxamide ribonucleotide transformylase (ATIC), and thymidylate synthase (TS), compared to naïve methotrexate. Among all the MTXPGs, methotrexate polyglutamate three (MTXPG-3) is a more potent inhibitor of DHFR, ATIC, and TS enzymes. MTXPG-3 is anticipated to allow therapeutic drug monitoring in immune-mediated inflammatory diseases. We aim to study MTXPG-3 levels as a biomarker for both efficacy and adverse events among psoriatic patients treated with methotrexate monotherapy. We used the LC-MS/MS (Liquid Chromatography Mass Spectrophotometry) system for measuring erythrocyte MTXPG-3. We recruited 106 patients with psoriasis who were treated with methotrexate. Sixty-one of them had psoriatic arthritis (concomitant or in the past). The mean age was 45.08 ± 13.04 years. After twenty-four weeks of methotrexate treatment, 73(69%) were responders, and 33(31%) were non-responders. Thirty-nine (36%) experienced adverse effects, and 67(64%) did not experience any adverse effects. We observed a significant positive correlation between erythrocyte MTXPG-3 and methotrexate dose per week at weeks 12 and 16 but not at week 24. Erythrocyte MTXPG-3 did not correlate with response or adverse effects. It can be used as a marker of compliance. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12291-024-01269-x.

Department of Biochemistry JIPMER Puducherry 06 India

Department of Dermatology JIPMER Puducherry 06 India

Department of Pharmacology JIPMER Puducherry 06 India

Institute of Molecular and Translational Medicine University of Palacky Olomouc Czech Republic

Zobrazit více v PubMed

Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis Lancet. 2021;397(10281):1301–15. PubMed

Cronstein BN, Aune TM. Methotrexate and its mechanisms of action in inflammatory arthritis. Nat Rev Rheumatol. 2020;16(3):145–54. PubMed

Ranganathan P. The challenges of methotrexate pharmacogenetics in rheumatoid arthritis. Pharmacogenomics. 2012;13(4):377. PubMed

Rohr MK, Mikuls TR, Cohen SB, Thorne JC, O’Dell JR. Underuse of Methotrexate in the treatment of rheumatoid arthritis: a National Analysis of Prescribing practices in the US. Arthritis Care Res. 2017;69(6):794–800. PubMed

Lafforgue P, Monjanel-Mouterde S, Durand A, Catalin J, Acquaviva PC. Lack of correlation between pharmacokinetics and efficacy of low dose methotrexate in patients with rheumatoid arthritis. J Rheumatol. 1995;22(5):844–9. PubMed

Henderson GB, Tsuji JM, Kumar HP. Characterization of the individual transport routes that mediate the influx and efflux of methotrexate in CCRF-CEM human lymphoblastic cells. Cancer Res. 1986;46(4 Pt 1):1633–8. PubMed

Cascorbi I. P-glycoprotein: tissue distribution, substrates, and functional consequences of genetic variations. In: Fromm M, Kim R, editors. Drug transporters. Handbook of experimental pharmacology. 2011; 201. Springer, Berlin, Heidelberg. PubMed

Chabner BA, Allegra CJ, Curt GA, Clendeninn NJ, Baram J, Koizumi S, et al. Polyglutamation of methotrexate. Is methotrexate a prodrug? J Clin Invest. 1985;76(3):907–12. PubMed PMC

Pan S, Stamp LK, Duffull SB, Barclay ML, Dalrymple JM, Drake J, et al. Assessment of the Relationship between Methotrexate Polyglutamates in Red Blood cells and clinical response in patients commencing methotrexate for rheumatoid arthritis. Clin Pharmacokinet. 2014;53(12):1161–70. PubMed

Allegra CJ, Drake JC, Jolivet J, Chabner BA. Inhibition of phosphoribosylaminoimidazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates. Proc Natl Acad Sci U S A. 1985;82(15):4881–5. PubMed PMC

Allegra CJ, Chabner BA, Drake JC, Lutz R, Rodbard D, Jolivet J. Enhanced inhibition of thymidylate synthase by methotrexate polyglutamates. J Biol Chem. 1985;260(17):9720–6. PubMed

Woolf RT, West SL, Arenas-Hernandez M, Hare N, van Peters AM, Lewis CM, et al. Methotrexate polyglutamates as a marker of patient compliance and clinical response in psoriasis: a single-centre prospective study. Br J Dermatol. 2012;167(1):165–73. PubMed

de Rotte MCFJ, den Boer E, de Jong PHP, Pluijm SMF, Ćalasan MB, Weel AE, et al. Methotrexate polyglutamates in erythrocytes are associated with lower disease activity in patients with rheumatoid arthritis. Ann Rheum Dis. 2015;74(2):408–14. PubMed

Sandhu A, Dhir V, Bhatnagar A, Dhawan V, Kaur J, Sood A, et al. High Methotrexate Triglutamate Level is an independent predictor of adverse effects in Asian Indian rheumatoid arthritis Patients-A preliminary study. Ther Drug Monit. 2017;39(2):157–63. PubMed

Stamp LK, O’Donnell JL, Chapman PT, Zhang M, Frampton C, James J, et al. Determinants of red blood cell methotrexate polyglutamate concentrations in rheumatoid arthritis patients receiving long-term methotrexate treatment. Arthritis Rheum. 2009;60(8):2248–56. PubMed

Becker ML, van Haandel L, Gaedigk R, Lasky A, Hoeltzel M, Stobaugh J, et al. Analysis of intracellular methotrexate polyglutamates in patients with juvenile idiopathic arthritis: Effect of route of administration on variability in intracellular methotrexate polyglutamate concentrations. Arthritis Rheum. 2010;62(6):1803–12. PubMed

Van De Meeberg MM, Hebing RCF, Nurmohamed MT, Fidder HH, Heymans MW, Bouma G, et al. A meta-analysis of methotrexate polyglutamates in relation to efficacy and toxicity of methotrexate in inflammatory arthritis, colitis and dermatitis. Br J Clin Pharmacol. 2023;89(1):61–79. PubMed PMC

Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54(8):2665–73. PubMed

Solomon DH, Glynn RJ, Karlson EW, Lu F, Corrigan C, Colls J, et al. Adverse effects of low-dose methotrexate: a randomized trial. Ann Intern Med. 2020;172(6):369–80. PubMed PMC

den Boer E, Meesters RJW, Van Zelst BD, Luider TM, Hazes JMW, Heil SG, et al. Measuring methotrexate polyglutamates in red blood cells: a new LC-MS/MS-based method. Anal Bioanal Chem. 2013;405(5):1673–81. PubMed

Hobl EL, Jilma B, Erlacher L, Duhm B, Mustak M, Bröll H, et al. A short-chain methotrexate polyglutamate as outcome parameter in rheumatoid arthritis patients receiving methotrexate. Clin Exp Rheumatol. 2012;30(2):156–63. PubMed

Hroch M, Chladek J, Simkova M, Vaneckova J, Grim J, Martinkova J. A pilot study of pharmacokinetically guided dosing of oral methotrexate in the initial phase of psoriasis treatment. J Eur Acad Dermatol Venereol. 2008;22(1):19–24. PubMed

Chladek J, Grim J, Martinkova J, Simkova M, Vaneckova J. Low-dose methotrexate pharmacokinetics and pharmacodynamics in the therapy of severe psoriasis. Basic Clin Pharmacol Toxicol. 2005;96(3):247–8. PubMed

Ćalasan MB, Den Boer E, De Rotte MC, Vastert SJ, Kamphuis S, De Jonge R, et al. Methotrexate polyglutamates in erythrocytes are associated with lower disease activity in juvenile idiopathic arthritis patients. Ann Rheum Dis. 2015;74(2):402–7. PubMed

Chládek J, Simková M, Vanecková J, Hroch M, Chládkova J, Martínková J, et al. The effect of folic acid supplementation on the pharmacokinetics and pharmacodynamics of oral methotrexate during the remission-induction period of treatment for moderate-to-severe plaque psoriasis. Eur J Clin Pharmacol. 2008;64(4):347–55. PubMed

Takahashi C, Kaneko Y, Okano Y, Taguchi H, Oshima H, Izumi K, et al. Association of erythrocyte methotrexate-polyglutamate levels with the efficacy and hepatotoxicity of methotrexate in patients with rheumatoid arthritis: a 76-week prospective study. RMD Open. 2017;3(1):e000363. PubMed PMC